{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T01:09:16Z","timestamp":1787792956617,"version":"build-2784847793"},"reference-count":12,"publisher":"BMJ","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Reports"],"accepted":{"date-parts":[[2017,2,9]]},"abstract":"<jats:p>A 70-year-old man with known cardiovascular risk factors, presented with acute onset expression aphasia, agraphia, dyscalculia, right-left disorientation and finger agnosia, without fever or meningeal signs. Stroke was thought to be the cause, but cerebrovascular disease investigation was negative. Interviewing the family revealed he had undergone yellow fever vaccination 18\u2005days before. Lumbar puncture revealed mild protein elevation. Cultural examinations,<jats:italic>Coxiella burnetti,<\/jats:italic>and neurotropic virus serologies were negative. Regarding the yellow fever virus, IgG was identified in serum and cerebrospinal fluid (CSF), with negative IgM and virus PCR in CSF. EEG showed an encephalopathic pattern. The patient improved gradually and a week after discharge was his usual self. Only criteria for suspect neurotropic disease were met, but it's possible the time spent between symptom onset and lumbar puncture prevented a definite diagnosis of yellow fever vaccine-associated neurological disease. This gap would have been smaller if the vaccination history had been collected earlier.<\/jats:p>","DOI":"10.1136\/bcr-2016-218706","type":"journal-article","created":{"date-parts":[[2017,3,2]],"date-time":"2017-03-02T16:00:25Z","timestamp":1488470425000},"page":"bcr2016218706","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":10,"title":["Yellow fever vaccine-associated neurological disease, a suspicious case"],"prefix":"10.1136","volume":"2017","author":[{"given":"Pedro","family":"Beir\u00e3o","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patr\u00edcia","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreia","family":"Nunes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Antunes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2017,3,2]]},"reference":[{"key":"2025042705325722000_2017.mar02_1.bcr2016218706.1","doi-asserted-by":"publisher","DOI":"10.1586\/erv.12.6"},{"key":"2025042705325722000_2017.mar02_1.bcr2016218706.2","first-page":"465","article-title":"Yellow fever surveillance and outbreak response: revision of case definitions, October 2010","volume":"85","author":"World Health Organization","year":"2010","journal-title":"Wkly Epidemiol Rec"},{"key":"2025042705325722000_2017.mar02_1.bcr2016218706.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2014.08.030"},{"key":"2025042705325722000_2017.mar02_1.bcr2016218706.4","doi-asserted-by":"crossref","first-page":"533","DOI":"10.4269\/ajtmh.2002.66.533","article-title":"Comparative safety and immunogenicity of two yellow fever 17D vaccines (ARILVAX and YF-VAX) in a phase III multicenter, double-blind clinical trial","volume":"66","author":"Monath","year":"2002","journal-title":"Am J Trop Med Hyg"},{"key":"2025042705325722000_2017.mar02_1.bcr2016218706.5","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-3156.1999.00496.x"},{"key":"2025042705325722000_2017.mar02_1.bcr2016218706.6","unstructured":"Staples JE , Gershman M , Fischer M . Centers for Disease Control and Prevention (CDC). Yellow fever vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2010;59 (RR-7):1\u201327."},{"key":"2025042705325722000_2017.mar02_1.bcr2016218706.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2008.09.009"},{"key":"2025042705325722000_2017.mar02_1.bcr2016218706.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2005.01.089"},{"key":"2025042705325722000_2017.mar02_1.bcr2016218706.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2013.01.054"},{"key":"2025042705325722000_2017.mar02_1.bcr2016218706.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2014.08.051"},{"key":"2025042705325722000_2017.mar02_1.bcr2016218706.11","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1002\/jmv.22236","article-title":"Intrathecal antibody production in two cases of yellow fever vaccine associated neurotropic disease in Argentina","volume":"83","author":"Pires-Marczeski","year":"2011","journal-title":"J Med Virol"},{"key":"2025042705325722000_2017.mar02_1.bcr2016218706.12","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3181e7c9dd"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2016-218706","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,27]],"date-time":"2025-04-27T12:33:03Z","timestamp":1745757183000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2016-218706"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,2]]},"references-count":12,"alternative-id":["10.1136\/bcr-2016-218706"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2016-218706","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,2]]}}}